Altering the Course of Disease

Using KB proprietary methods, KB has identified and eliminates a primary driver of our most deadly diseases, Porphyromonas gingivalis and all of it’s unique virulence factors.

KB is changing the paradigm of inflammatory based disease with precision bio-therapeutics and diagnostics to eliminate a chronic, foreign, bacterial source in the body thereby reducing systemic inflammation.



Keystone Bio is a clinical stage, biopharmaceutical company with novel disease-modifying, precision, anti-bacterial bio-therapeutics to target an important and largely unaddressed bacterial driver of systemic inflammation that significantly contribute to multiple inflammatory diseases such as heart disease and dementia/Alzheimer’s disease along with companion diagnostics to diagnose/identify people at risk and monitor treatment.

KB is advancing a clinically validated bio-therapeutic treatment (KB-001 Mab) for the elimination of Porphyromonas gingivalis and all of it’s virulence factors including the outer membrane vesicles and their toxic protein complex.

Chronic inflammatory diseases have been recognized as the most significant cause of death in the world today, with more than 50% of all deaths being attributable to inflammation-related diseases such as ischemic heart disease, stroke, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease (NAFLD) and autoimmune and neurodegenerative conditions.

Using KB proprietary methods, KB has discovered a bacterial toxic protein that is a primary driver of systemic inflammation. This bacterial toxic protein complex is secreted actively in large amounts by the bacteria for it’s own survival, however has off site systemic pathology in various end organs such as the brain in AD brain tissues. This virulent protein complex is packaged into distinct outer membrane vesicles, breaking down and crossing the BBB, and impacts the brain parenchyma in specific neuro-anatomic locations consistent with AD development.





Monoclonal antibody with unique binding to P. gingivalis toxin/survival complex KB-001 has already been shown in its first clinical study to prevent long term recolonization, thereby eliminating all of the virulence factors of P.g. contributing to systemic/organ-based inflammation at their source.

KBhu-007 and KBhu-0014

Humanized chimeric monoclonal antibody candidates with similar binding to Porphyromonas gingivalis, ready for drug development.

KBd-001 and KBd-002

Two Companion of diagnostics -one for genotyping the bacteria and one for measuring the toxic vesicles in the blood. — in development.


Vaccine development targeting same protein complex as KB-001 Mab.

Our Team

Scientific Advisory Board

keystone_team_0007_Vector Smart Object

Garth Erhlich


Director Center for Genomic Sciences Institute of Molecular Medicine and Infectious Disease Genomics Core Facility Clinical and Translational Research Institute Professor of Microbiology and Immunology Professor of Otolaryngology - Head and Neck Surgery Executive Director Center for Advanced Microbial Processing (CAMP) Institute of Molecular Medicine and Infectious Disease

keystone_team_0006_Vector Smart Object

Marc Penn


Former Medical Director, Cardiac ICU, Cleveland Clinic

Former Director, Bakken Heart-Brain Institute

Chief Medical Officer, Cleveland Heart Lab

Professor of Integrative Medical Sciences, Northeast Ohio Medical University

5eba9a855c30246137acfe87_No-Hee Park

No-Hee Park

Dean Emeritus and Distinguished Professor of Dentistry, UCLA School of Dentistry and Distinguished Professor of Medicine, David Geffen School of Medicine at UCLA
keystone_team_0004_Vector Smart Object

StJohn Crean


Executive Dean of College of Clinical and Biomedical Sciences, University of Central Lancashire

Robert Bradlaw advisor, Faculty of Dental Surgery at the Royal College of Surgeons of England

Editor-in-Chief, Faculty Dental Journal

keystone_team_0003_Vector Smart Object

W. Sue T. Griffin


Editor-in-Chief, Journal ofNeuroinflammation

Dillard Professor & Vice Chairman, Donald W. Reynolds Dept. of Geriatrics, University of Arkansas for Medical Sciences

Director of Research, Geriatric Research, Education and Clinical Center, VAMC/CAVHS

keystone_team_0002_Vector Smart Object

Judith Miklossy


Director, International Foundation for Alzheimer’s Prevention

Harvard Distinguished Service Award


Sim K. Singhrao


Senior Research Fellow, University of Central Lancashire School of Medicine & Dentistry

keystone_team_0000_Vector Smart Object

Rita Cowell


Founder Chairman COSMOS ID

Distinguished University Professor at the University of Maryland College Park and at Johns Hopkins University Bloomberg School of Public Health
Eleventh director of the National Science Foundation (NSF) from 1998 to 2004 2006 National Medal of Science (given by President George W. Bush)


Jon Potempa

Ph.D., D.Sc.

Biochemist and microbiologist. Leads research on bacteria causing periodontal diseases He received his Master's degree in 1979 at the Jagiellonian University. It is also at this university that he received his PhD (1982) and postdoctoral (1993) degrees, i.e. habilitation. A professor since 1998. Member of the Polish Biochemical Society, International Association of Dental Research, International Proteolysis Society and the American Microbiology Society. Laureate of the Prime Minister's Avvard for exceptional Science. Laureate of the Prime Minister's Avvard for exceptional scientific achievements (2001) as well as of the 2004 MISTRZ (“MASTER") and 2009 “TEAM" programs of the Foundation for Polish Science.

Our Team

Executive Management


Daniel Sindelar DMD


Saint Louis University class of ‘77 majored in Accounting, Biology, and MacroEconomics and Washington University School of Dental Medicine class of ’81. Over the last 10 years has played the lead role globally in establishing of oral pathogens causality of systemic disease including Cardiovascular disease and Alzheimer’s disease. He is the founder and past President of the American Academy for Oral Systemic Health and the first Dental Professional to take a Preceptorship for Heart Attack and Stroke Prevention for Cardiologists. Continued his business education by participating in a Harvard Executive Management Program focusing on founders of successful startups.


Peter Nara, DVM, Ph.D.


Chairman Emeritus/Past President/CEO/Chairman of the Board of Biological Mimetics, has 18 years of successful co-founding Biological Mimetics, Inc., Lantern Pharma and Keystone Bio Inc.. Formerly Section Chief National Cancer Institute 16 years. Elected a Fellow to the American Association for the Advancement of Science in 2011. Biological Program Leader for FUN BIO PROGRAM/DARPA .

keystone_team_0006_Vector Smart Object

Marc Penn


Former Director of the Coronary Intensive Care Unit, Director of the Experimental Animal Laboratory, Director of the Bakken Heart-Brain Institute, and the Founding Director of the Center for Cardiovascular Cell Therapy. Former CEO of Black Beret Life Sciences (Houston, TX). As CEO of Black Beret Life Sciences, LLC, oversaw the life science investments of the Bosarge Family Office and leads the executive team of numerous companies including Tissue Genesis, LLC, (Honolulu, HI), Advanced Regen Medical Technologies, LLC, (Newark NJ), the novel sugar replacement Sola (Houston, TX), and the stem cell treatment center, Okyanos (Freeport Bahamas), where he is also the Director of Research and Strategy. He serves on the BOD of Frantz Viral Therapeutics (Cleveland, OH) and Affigen (St. Louis, MO), and is an advisor to Diasome and Quest Diagnostics (Cleveland, OH) and Director of Research and of the Cardiovascular Medicine Fellowship at the Summa Cardiovascular Institute, Summa Health (Akron, OH) and Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University where he led the Skirball Laboratory for Cardiovascular Cellular Therapeutics (Rootstown, OH). From 2000-11